Michèle is a co-founder and Partner at Medicxi. Prior to Medicxi, Michèle was a Partner at Index Ventures for 10 years, having joined the firm in 2006. She has led investments in, and continues to serve on the boards of, Palladio Biosciences, Kaerus Biosciences, Villaris Therapeutics, Pearl River Bio, Alderaan Biotechnology and Yukin Therapeutics. She was also a director at OncoEthix (sold to Merck Pharmaceuticals), Minerva Neurosciences (NASDAQ: NERV) and Aegerion (NASDAQ: AEGR).
Prior to joining Index, Michèle was Investment Director at Edmond de Rothschild Investment Partners in Paris for 3 years, where she served on the board of U3 Pharma. Before that, she spent more than 15 years in several development and marketing positions at Sanofi International, BMS, RPR/ Gencell/ Aventis International and Serono International.
She currently serves on the board of directors of Ipsen Pharmaceuticals (Euronext:IPN). She also sits on the investment committees of the accelerator and technology transfer companies of Paris-Saclay and France-Nord.
Michèle completed her medical studies in France at Paris Ouest University.